Restricted accessResearch articleFirst published online 2025-08
Small Animal Positron Emission Tomography Imaging of a Triple-Negative Breast Cancer Model Using the 68 Ga-Labeled pH (Low) Insertion Peptide-Like Peptide YJL-11
To prepare a novel 68Ga-labeled pH (low) insertion peptide-like peptide, YJL-11, and study its ability to be used as a probe for the diagnosis of triple-negative breast cancer (TNBC) via in vivo imaging of tumor-bearing nude mice.
Methods:
Circular dichroism (CD) analysis of YJL-11 was performed to assess its secondary structure. YJL-11 was labeled with 68Ga, and the in vivo biodistribution of 68Ga-YJL-11 in MDA-MB-231 xenograft mice was evaluated. This probe was then applied for small animal positron emission tomography (PET) imaging of tumor-bearing nude mice.
Results:
CD analysis of YJL-11 confirmed a typical pH-dependent transition in its secondary structure. The radiochemical yield of 68Ga-YJL-11 was 75.5 ± 0.25%, and the radiochemical purity was 95.75 ± 0.15%. Biodistribution studies showed that the tumor uptake of 68Ga-YJL-11 was significantly higher than in the control group, 1 and 2 h after injection. Small animal PET imaging results were consistent with the biodistribution data, showing clear images of the tumors and livers 1 and 2 h after injection of 68Ga-YJL-11, whereas tumors were not detected in the control group.
Conclusion:
68Ga-YJL-11 was prepared with high radiochemical yield and can target TNBC tissues, indicating that it has great potential in the diagnosis of TNBC.
Get full access to this article
View all access options for this article.
References
1.
SiegelRL, GiaquintoAN, JemalA. Cancer statistics, 2024. CA Cancer J Clin, 2024; 74(1):12–49; doi: 10.3322/caac.21830
2.
DentR, TrudeauM, PritchardKI, et al.Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res, 2007; 13(15 Pt 1):4429–4434; doi: 10.1158/1078-0432.CCR-06-3045
3.
ErićI, Petek ErićA, KristekJ, et al.Breast cancer in young women: Pathologic and immunohistochemical features. Acta Clin Croat, 2018; 57(3):497–502; doi: 10.2047/1/acc.2018.57.03.13
4.
HenryKE, DillingTR, Abdel-AttiD, et al.Noninvasive 89Zr-Transferrin PET shows improved tumor targeting compared with 18F-FDG PET in MYC-Overexpressing human triple-negative breast cancer. J Nucl Med, 2018; 59(1):51–57; doi: 10.2967/jnumed.117.192286
5.
de JongD, DesperitoE, Al FeghaliKA, et al.Advances in PET/CT imaging for breast cancer. J Clin Med, 2023; 12(13):4537; doi: 10.3390/jcm12134537
6.
Terwisscha van ScheltingaAG, BerghuisP, NienhuisHH, et al.Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer. Eur J Cancer, 2014; 50(14):2508–2516; doi: 10.1016/j.ejca.2014.06.008
7.
GaykemaSB, BrouwersAH, Lub-de HoogeMN, et al.89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med, 2013; 54(7):1014–1018; doi: 10.2967/jnumed.112.117218
8.
KratochwilC, GieselFL, EderM, et al.[177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging, 2015; 42(6):987–988; doi: 10.1007/s00259-014-2978-1
9.
HuntJF, EarnestTN, BouschéO, et al.A biophysical study of integral membrane protein folding. Biochemistry, 1997; 36(49):15156–15176; doi: 10.1021/bi970146j
10.
WeerakkodyD, MoshnikovaA, ThakurMS, et al.Family of pH (low) insertion peptides for tumor targeting. Proc Natl Acad Sci U S A, 2013; 110(15):5834–5839; doi: 10.1073/pnas.1303708110
11.
PathakAP, GimiB, GlundeK, et al.Molecular and functional imaging of cancer: Advances in MRI and MRS. Methods Enzymol, 2004; 386:3–60; doi: 10.1016/S0076-6879(04)86001-4
12.
PenetMF, GlundeK, JacobsMA, et al.Molecular and functional MRI of the tumor microenvironment. J Nucl Med, 2008; 49(5):687–690; doi: 10.2967/jnumed.107.043349
13.
WyattLC, MoshnikovaA, CrawfordT, et al.Peptides of pHLIP family for targeted intracellular and extracellular delivery of cargo molecules to tumors. Proc Natl Acad Sci U S A, 2018; 115(12):E2811–E2818; doi: 10.1073/pnas.1715350115
14.
Vila-ViçosaD, SilvaTFD, SlaybaughG, et al.Membrane-Induced p Ka Shifts in wt-pHLIP and Its L16H Variant. J Chem Theory Comput, 2018; 14(6):3289–3297; doi: 10.1021/acs.jctc.8b00102
15.
GuptaC, RenY, MertzB. Cooperative Nonbonded forces control membrane binding of the pH-Low insertion peptide pHLIP. Biophys J, 2018; 115(12):2403–2412; doi: 10.1016/j.bpj.2018.11.002
16.
Bañó-PoloM, Martínez-GilL, BarreraFN, et al.Insertion of bacteriorhodopsin helix C variants into biological membranes. ACS Omega, 2020; 5(1):556–560; doi: 10.1021/acsomega.9b03126
17.
ReshetnyakYK, SegalaM, AndreevOA, et al.A monomeric membrane peptide that lives in three worlds: In solution, attached to, and inserted across lipid bilayers. Biophys J, 2007; 93(7):2363–2372; doi: 10.1529/biophysj.107.109967
18.
TapmeierTT, MoshnikovaA, BeechJ, et al.The pH low insertion peptide pHLIP Variant 3 as a novel marker of acidic malignant lesions. Proc Natl Acad Sci U S A, 2015; 112(31):9710–9715; doi: 10.1073/pnas.1509488112
19.
ReshetnyakYK, YaoL, ZhengS, et al.Measuring tumor aggressiveness and targeting metastatic lesions with fluorescent pHLIP. Mol Imaging Biol, 2011; 13(6):1146–1156; doi: 10.1007/s11307-010-0457-z
AdochiteRC, MoshnikovaA, CarlinSD, et al.Targeting breast tumors with pH (low) insertion peptides. Mol Pharm, 2014; 11(8):2896–2905; doi: 10.1021/mp5002526
22.
AdochiteRC, MoshnikovaA, GolijaninJ, et al.Comparative Study of Tumor Targeting and Biodistribution of pH (Low) Insertion Peptides (pHLIP(®) Peptides) Conjugated with Different Fluorescent Dyes. Mol Imaging Biol, 2016; 18(5):686–696; doi: 10.1007/s11307-016-0949-6
23.
GolijaninJ, AminA, MoshnikovaA, et al.Targeted imaging of urothelium carcinoma in human bladders by an ICG pHLIP peptide ex vivo. Proc Natl Acad Sci U S A, 2016; 113(42):11829–11834; doi: 10.1073/pnas.1610472113
24.
RahmanA, JanicB, RahmanT, et al.Immunotherapy enhancement by targeting extracellular tumor pH in triple-negative breast cancer mouse model. Cancers (Basel), 2023; 15(20):4931; doi: 10.3390/cancers15204931
25.
ChenY, SongS, SunY, et al.Small animal PET imaging with the 68Ga-labeled pH (low) insertion peptide-like peptide YJL-4 in a triple-negative breast cancer mouse model. EJNMMI Radiopharm Chem, 2024; 9(1):33; doi: 10.1186/s41181-024-00267-x
26.
ChenY, SuY, PangX, et al.Synthesis and evaluation of Technetium-99 m-Labeled pH (Low) insertion peptide variant 7 for early diagnosis of MDA-MB-231 triple-negative breast cancer by targeting the tumor microenvironment. Front Oncol, 2022; 12:869260; doi: 10.3389/fonc.2022.869260
27.
WuF, ChenY, LiD, et al.Synthesis and evaluation of radioiodine-labeled pH (Low) insertion peptide variant 7-like peptide as a noninvasive tumor microenvironment imaging agent in a mouse MDA-MB-231 triple-negative breast cancer model. Mol Imaging Biol, 2022; 24(4):570–579; doi: 10.1007/s11307-021-01702-0
28.
ChenYH, YuMM, WangZG. Inhibition of MDA-MB-231 cell proliferation by pHLIP(Var7)-P1AP and SPECT imaging of MDA-MB-231 breast cancer-bearing nude mice using 125I-pHLIP(Var7)-P1AP. Nuklearmedizin, 2021; 60(3):240–248; doi: 10.1055/a-1307-1923
29.
YuM, SunY, YangG, et al.An experimental study on [125I]I-pHLIP (Var7) for SPECT/CT imaging of an MDA-MB-231 triple-negative breast cancer mouse model by targeting the tumor microenvironment. Mol Imaging, 2021; 2021:5565932; doi: 10.1155/2021/5565932
30.
YuM, ChenY, WangZ, et al.pHLIP(Var7)-P1AP suppresses tumor cell proliferation in MDA-MB-231 triple-negative breast cancer by targeting protease activated receptor 1. Breast Cancer Res Treat, 2020; 180(2):379–384; doi: 10.1007/s10549-020-05560-2
ShenY, MaupetitJ, DerreumauxP, et al.Improved PEP-FOLD approach for peptide and miniprotein structure prediction. J Chem Theory Comput, 2014; 10(10):4745–4758; doi: 10.1021/ct500592m
33.
ThévenetP, ShenY, MaupetitJ, et al.PEP-FOLD: An updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res, 2012; 40(Web Server issue):W288–W293; doi: 10.1093/nar/gks419
34.
SosunovEA, AnyukhovskyEP, SosunovAA, et al.pH (low) insertion peptide (pHLIP) targets ischemic myocardium. Proc Natl Acad Sci U S A, 2013; 110(1):82–86; doi: 10.1073/pnas.1220038110
35.
CoenenHH, GeeAD, AdamM, et al.Consensus nomenclature rules for radiopharmaceutical chemistry - Setting the record straight. Nucl Med Biol, 2017; 55:v–vxi; doi: 10.1016/j.nucmedbio.2017.09.004
36.
VelikyanI, MaeckeH, LangstromB. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem, 2008; 19(2):569–573; doi: 10.1021/bc700341x
37.
FerreiraCL, YappDT, MandelD, et al.(68)Ga small peptide imaging: Comparison of NOTA and PCTA. Bioconjug Chem, 2012; 23(11):2239–2246; doi: 10.1021/bc300348d
38.
ChatalicKL, FranssenGM, van WeerdenWM, et al.Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. J Nucl Med, 2014; 55(12):2050–2056; doi: 10.2967/jnumed.114.141143
39.
WeiX, ZhaoH, HuangG, et al.ES-MION-Based Dual-Modality PET/MRI Probes for Acidic Tumor Microenvironment Imaging. ACS Omega, 2022; 7(4):3442–3451; doi: 10.1021/acsomega.1c05815
40.
MorgenrothA, TinkirE, VoggATJ, et al.Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer. Breast Cancer Res, 2019; 21(1):116; doi: 10.1186/s13058-019-1205-1
41.
DemoinDW, WyattLC, EdwardsKJ, et al.PET imaging of extracellular pH in tumors with (64)Cu- and (18)F-Labeled pHLIP peptides: A structure-activity optimization study. Bioconjug Chem, 2016; 27(9):2014–2023; doi: 10.1021/acs.bioconjchem.6b00306
42.
GallagherFA, KettunenMI, BrindleKM. Imaging pH with hyperpolarized 13C. NMR Biomed, 2011; 24(8):1006–1015; doi: 10.1002/nbm.1742Epub 2011 Aug 3
43.
HelmlingerG, YuanF, DellianM, et al.Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med, 1997; 3(2):177–182; doi: 10.1038/nm0297-177
44.
WojtkowiakJW, VerduzcoD, SchrammKJ, et al.Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm, 2011; 8(6):2032–2038; doi: 10.1021/mp200292c
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
